Semaglutide and male fertility: sperm findings are not pregnancy outcomes

The headline needs a population and an endpoint

A claim that semaglutide improves male fertility can sound broader than the research behind it. Ask whether the study measured semen characteristics, hormone levels, sexual function, pregnancy or live birth. Those outcomes answer different questions. I would not describe a semen change as proof that a couple is more likely to have a baby unless the study actually established that outcome. Keep the original paper at the center of the discussion and treat promising early findings as a reason for further research, not a commercial treatment guarantee.

What the small trial actually compared

The randomized open-label study involved 25 men with obesity, type 2 diabetes and functional hypogonadism. It compared semaglutide 1 mg weekly with testosterone undecanoate over 24 weeks. There were 13 participants assigned semaglutide and 12 testosterone. That selected population and active comparator matter. This was not a large placebo-controlled trial of otherwise healthy men trying to conceive. The findings therefore cannot be applied automatically to every man taking a GLP-1 product or to another medicine, dose or clinical situation.^[1]

Sperm morphology is not a live-birth result

The study reported improved normal sperm morphology in the semaglutide group and differences in semen parameters compared with the testosterone group. It did not establish pregnancy or live-birth benefit. A favorable change in a laboratory endpoint can be scientifically interesting while leaving the outcome a couple cares most about unanswered. Read the result with its comparator, sample size and follow-up attached. The paper’s optimistic conclusion should not be converted into a statement that semaglutide is a proven fertility treatment or that an individual will achieve the same change.^[1]

The comparator is part of the interpretation

ASRM’s male infertility guidance states that testosterone monotherapy should not be prescribed for men interested in current or future fertility. That context matters when interpreting a comparison with testosterone. It does not mean a person should stop an existing prescription independently. Tell the treating clinician about fertility goals and ask for an appropriate assessment of the whole regimen. A comparison against a treatment with its own fertility implications answers a different question from a comparison against no intervention or another fertility-directed approach.^[2]

Small and open-label require measured conclusions

NIH explains why study design affects the strength and interpretation of evidence. In a small open-label trial, participants and clinicians know which treatment is given, and the estimate may not represent a broader population. These features do not make the study useless. They do mean that a clear article should retain the uncertainty rather than use the strongest possible headline. Ask what larger, longer or differently designed study would be needed to confirm a clinical benefit and whether the measured outcomes match the claim being advertised.^[3] Our research-reading guide explains why design and endpoints should stay visible.

Bring reproductive goals into the medication review

If fertility is a current or future concern, tell the clinician before starting or changing weight-management, hormone or other treatment. Provide an accurate medicine list and relevant previous evaluations. Do not substitute an online semen target or a supplement bundle for a clinical assessment. A couple’s fertility question can require more than a single laboratory result from one partner. Ask who is coordinating care and whether a specialist is appropriate. This guide cannot determine the cause of infertility or select treatment for an individual.

Be cautious with combined wellness marketing

Some services sell weight-management and hormone-related care under one brand. That commercial arrangement does not establish that combining services improves fertility. Ask which clinician assesses reproductive goals, what is included and whether the proposed plan is consistent with those goals. I would not accept a trial citation as a substitute for that explanation. Our reviews help compare the model and costs; they do not endorse a hormone regimen, certify fertility outcomes or determine whether a particular combination is suitable. Our Defy Medical review and Joi and Blokes review provide service-model reading paths without implying fertility benefit.

A useful conclusion leaves the unanswered outcome visible

The research raises a specific question about semen parameters in a small group with defined conditions. It does not settle the effect on pregnancy, live birth or all men using GLP-1 medicines. Bring the original findings and your goals to a qualified clinician rather than choosing treatment from a headline. Keep access to appropriate follow-up beside the commercial quote. The most useful next step is a coordinated medication and fertility discussion, with the limits of the evidence stated clearly instead of filled by a promise. Use our appointment checklist to prepare the questions and records.

Explore relevant provider reviews

Use these reviews to compare the published services and terms. Inclusion is a research starting point, not a recommendation for treatment.

Continue your research

• Tirzepatide vs semaglutide: what SURMOUNT-5 actually found
• Weight regain after stopping GLP-1 treatment: what two studies show
• Wegovy and heart health: what SELECT actually showed